Share this article

Swiss biopharmaceutical company Ferring Pharmaceuticals has reported a positive outcome from the Phase III ESTHER-1 and ESTHER-2 clinical trials of its fertility drug, Rekovelle.

Rekovelle is a recombinant follicle-stimulating hormone (rFSH) extracted from a human cell line and is currently being developed to deliver individualised doses based on the body weight and serum AMH level of a patient.

The results indicated cumulative live birth rates similar to standard follitropin alfa treatment and a favourable safety profile in women with high levels of anti-Müllerian hormone (AMH).

The randomised, assessor-blind, controlled ESTHER-1 trial evaluated a fixed daily dose of Rekovelle in 1,326 patients across 11 countries, while the assessor-blind, controlled ESTHER-2 trial assessed the drug candidate’s immunogenicity in a subset of ESTHER-1 patients who were undergoing repeated cycles of controlled ovarian stimulation for ART.

"These new Rekovelle analyses add further evidence for a personalised approach to fertility treatment for patients."

Ferring Pharmaceuticals executive vice-president and chief scientific officer Per Falk said: “Rekovelle’s individualised dosing regimen, based on a patient’s AMH level and body weight, provides clinicians with a consistent, evidence-based approach to personalising treatment for their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“These new Rekovelle analyses add further evidence for a personalised approach to fertility treatment for patients.”

The data from both trials demonstrated a cumulative live birth rate of 43.9% with Rekovelle for fresh embryo transfers following three treatment cycles in subjects undergoing in-vitro fertilisation (IVF), while the rate with follitropin alfa was found to be 44.5%.

Additional analysis indicated a 45.1% ongoing pregnancy rate with Rekovelle and a rate of 45.7% with follitropin alfa.

Image: Ferring Pharmaceuticals headquarters in Switzerland. Photo: courtesy of Ferring International Center.